Business Wire
24 Aug 2026, 13:47 UTC · 12w ago
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
Impact · against what's priced in
The appointment of Jonathan M. Pratt as CEO of QIAGEN is a positive leadership transition, though the impact is tempered by the distant effective date of September 2026. The market will likely view his life sciences and healthcare experience as a net benefit for long-term strategy.
- QGEN+0.10
No priced-in read yet
- In context
The appointment of an experienced life sciences leader as CEO is positive, but the impact is minimal due to the appointment not taking effect until September 1, 2026.
Read from the article alone

Top 1 mover · tap to explore




